Legend Biotech has seen its stock swing sharply in recent years, while fresh progress on its CAR T pipeline has kept it on investors' radar. With the share price around US$21.56 after those moves, the live question is whether that tag still lines up with what the business is doing on the sales side.
-
Over the past 3 years the stock has fallen 67.4%, which puts the focus squarely on whether the current valuation is now more closely tied to the revenue it generates.
-
The recent FDA clearance for Legend Biotech's in vivo dual targeting CAR T trial may support expectations for future sales, but it can also shift the timing and risk profile of when those potential cash inflows might arrive.
-
There is a second opinion on Legend Biotech worth weighing. See what analysts think Legend Biotech's shares could be worth .
The issue now is whether the current share price of Legend Biotech is adequately supported by its sales when assessed against the Fair Ratio benchmark.
If you are weighing Legend Biotech against other potential ideas in the same phase of your research, it can help to compare its setup with companies in our screener containing 21 high quality undiscovered gems .
Is Legend Biotech Still Cheap on Sales?
P/S is a useful lens for Legend Biotech because investors are mainly paying for current and potential revenue rather than established earnings. On this metric, Legend Biotech trades on a P/S of 3.3x, which is below the broader Biotechs industry average of 11.3x and also under the peer group level of 7.5x.
The Fair Ratio, which adjusts the P/S benchmark for Legend Biotech's own growth profile, margins, size and risks, sits above the current market multiple. On this framework, the stock screens as undervalued. Because the FDA clearance for the in vivo dual targeting CAR T trial has put fresh attention on the pipeline, that discount on sales may suggest investors are still cautious about how much of that potential will translate into consistent revenue. Explore the numbers behind Legend Biotech's P/S valuation .
The Legend Biotech Narrative: What Would Justify Today's Price?
Narratives pick up where the valuation puzzle for Legend Biotech leaves off by explaining which assumptions about future growth, profitability and earnings power would need to hold for the stock to be worth materially more or materially less than today's price on Simply Wall St's Community page. Each scenario connects a fair value estimate to a clear story about Legend Biotech's possible catalysts and setbacks, allowing you to track over time which version is actually unfolding.
One of the top community narratives on Legend Biotech: 68% undervalued
"The current valuation indicates that the market may be assigning limited value to Legend Biotech's transition to adjusted profitability and to its efforts to develop CARVYKTI and in vivo CAR-T as potential long-term cash flow sources for shareholders…"
Discover why this Narrative puts Legend Biotech at 68% undervalued .
One More Angle On Legend Biotech That Could Shift Your View
Everything so far has focused on what Legend Biotech looks like today, yet professional coverage also sketches out where they expect this business to be a few years from now. This gives you a different benchmark to measure against. Explore where analysts expect Legend Biotech to be in a few years .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LEGN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
